Coagulopathy post peritoneovenous shunt.
PDF (1.7M)
Journal: 1987/April - Annals of Surgery
ISSN: 0003-4932
PUBMED: 3103556
Abstract:
In 1942, 53% of medically treated patients with cirrhosis were dead 6 months after the onset of ascites. Only 30% survived 1 year. This dismal outlook has improved only slightly with advances in medicine. Yet, some internists reject the peritoneovenous shunt (PVS) for this fatal condition even if they are aware that a diminished blood volume causes the abnormal sodium retention responsible for ascites. Their objections are based on life-threatening complications of PVS, especially post shunt coagulopathy (PSC). Blood shed into the peritoneal cavity becomes incoagulable. Such blood is immediately coagulated by a protocoagulant (soluble collagen) and concurrently lysed by tissue plasminogen activator (TPA) secreted by the peritoneal serosa. Wide zones of lysis surround peritoneal tissue placed on fibrin plates. Large volumes of ascitic fluid infused into circulating blood simulates the fate of blood shed into the peritoneal cavity with lysis playing the major role. Addition of ascitic fluid to normal platelet-rich plasma in vitro initiates clot lysis on thromboelastogram (TEG). Epsilon-aminocaproic acid (EACA) counteracts this lysis. EACA and clotting factors normalize the TEG and arrest PSC. Disposal of ascitic fluid at surgery prevents or ameliorates PSC. Mild PSC was encountered only twice in 150+ consecutive patients (1.3%) with only one case being clinically significant (0.6%). Severe PSC occurred seven times in 98 early shunt patients whose ascitic fluid was not discarded. Severe PSC requires shunt interruption and control of bleeding with clotting factors and EACA. Peritoneal lavage with saline prevents the recurrence of PSC on reopening the shunt. In four patients, EACA and clotting factors were adequate to arrest coagulopathy. Three earlier patients died of PSC before its cause and treatment were understood. Proper management eliminates this life-threatening complication, and PSC cannot be considered a deterrent to PVS. Disseminated intravascular coagulopathy (DIC) is produced in experimental animals only by the injection of thrombin or thromboplastin. PSC is a distinct entity differing from DIC; EACA and not heparin is the antidote for PSC.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(1)
References
(42)
Diseases
(1)
Conditions
(1)
Drugs
(3)
Chemicals
(2)
Organisms
(1)
Anatomy
(1)
Similar articles
Articles by the same authors
Discussion board
Ann Surg 205(3): 305-311
PMID: 3103556

Coagulopathy post peritoneovenous shunt.

Abstract

In 1942, 53% of medically treated patients with cirrhosis were dead 6 months after the onset of ascites. Only 30% survived 1 year. This dismal outlook has improved only slightly with advances in medicine. Yet, some internists reject the peritoneovenous shunt (PVS) for this fatal condition even if they are aware that a diminished blood volume causes the abnormal sodium retention responsible for ascites. Their objections are based on life-threatening complications of PVS, especially post shunt coagulopathy (PSC). Blood shed into the peritoneal cavity becomes incoagulable. Such blood is immediately coagulated by a protocoagulant (soluble collagen) and concurrently lysed by tissue plasminogen activator (TPA) secreted by the peritoneal serosa. Wide zones of lysis surround peritoneal tissue placed on fibrin plates. Large volumes of ascitic fluid infused into circulating blood simulates the fate of blood shed into the peritoneal cavity with lysis playing the major role. Addition of ascitic fluid to normal platelet-rich plasma in vitro initiates clot lysis on thromboelastogram (TEG). Epsilon-aminocaproic acid (EACA) counteracts this lysis. EACA and clotting factors normalize the TEG and arrest PSC. Disposal of ascitic fluid at surgery prevents or ameliorates PSC. Mild PSC was encountered only twice in 150+ consecutive patients (1.3%) with only one case being clinically significant (0.6%). Severe PSC occurred seven times in 98 early shunt patients whose ascitic fluid was not discarded. Severe PSC requires shunt interruption and control of bleeding with clotting factors and EACA. Peritoneal lavage with saline prevents the recurrence of PSC on reopening the shunt. In four patients, EACA and clotting factors were adequate to arrest coagulopathy. Three earlier patients died of PSC before its cause and treatment were understood. Proper management eliminates this life-threatening complication, and PSC cannot be considered a deterrent to PVS. Disseminated intravascular coagulopathy (DIC) is produced in experimental animals only by the injection of thrombin or thromboplastin. PSC is a distinct entity differing from DIC; EACA and not heparin is the antidote for PSC.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.7M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
icon of scanned page 305
305
icon of scanned page 306
306
icon of scanned page 307
307
icon of scanned page 308
308
icon of scanned page 309
309
icon of scanned page 310
310
icon of scanned page 311
311

Images in this article

Fig. 1.
Fig. 1.
on p.306
Fig. 2.
Fig. 2.
on p.307
Fig. 4.
Fig. 4.
on p.308
Fig. 5.
Fig. 5.
on p.309
Fig. 6.
Fig. 6.
on p.309
Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Powell WJ, Jr, Klatskin G. Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med. 1968 Mar;44(3):406–420. [PubMed] [Google Scholar]
  • Vesin P. Potassium supplements and diuretics. Lancet. 1972 Dec 9;2(7789):1262–1263. [PubMed] [Google Scholar]
  • EISENMENGER WJ, BLONDHEIM SH, BONGIOVANNI AM, KUNKEL HG. Electrolyte studies on patients with cirrhosis of the liver. J Clin Invest. 1950 Nov;29(11):1491–1499.[PMC free article] [PubMed] [Google Scholar]
  • Epstein M. Renal sodium handling in cirrhosis: a reappraisal. Nephron. 1979;23(5):211–217. [PubMed] [Google Scholar]
  • Arroyo V, Rodés J. A rational approach to the treatment of ascites. Postgrad Med J. 1975 Aug;51(598):558–562.[PMC free article] [PubMed] [Google Scholar]
  • Epstein M. Peritoneovenous shunt in the management of ascites and the hepatorenal syndrome. Gastroenterology. 1982 Apr;82(4):790–799. [PubMed] [Google Scholar]
  • Cooper HA, Bowie EJ, Owen CA., Jr Chronic induced intravascular coagulation in dogs. Am J Physiol. 1973 Dec;225(6):1355–1358. [PubMed] [Google Scholar]
  • HARDAWAY RM, WATSON HE, WEISS FH. Alterations in blood coagulation mechanism after intra-aortic injection of thrombin. Arch Surg. 1960 Dec;81:983–991. [PubMed] [Google Scholar]
  • Tawes RL, Jr, Sydorak GR, Kennedy PA, Brown WH, Scribner RG, Beare JP, Harris EJ. Coagulopathy associated with peritoneovenous shunting. Am J Surg. 1981 Jul;142(1):51–55. [PubMed] [Google Scholar]
  • Harmon DC, Demirjian Z, Ellman L, Fischer JE. Disseminated intravascular coagulation with the peritoneovenous shunt. Ann Intern Med. 1979 May;90(5):774–776. [PubMed] [Google Scholar]
  • Merskey C, Kleiner GJ, Johnson AJ. Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. Blood. 1966 Jul;28(1):1–18. [PubMed] [Google Scholar]
  • Merskey C. Defibrination syndrome or? Blood. 1973 Apr;41(4):599–603. [PubMed] [Google Scholar]
  • Puig JG, Antón FM, González JM, Vázquez JO. Peritoneovenous shunt and bacterial endotoxin. Mayo Clin Proc. 1979 Feb;54(2):133–133. [PubMed] [Google Scholar]
  • Fumarola D. Endotoxin and coagulopathic disorders after ascitic fluid infusion. Mayo Clin Proc. 1979 Dec;54(12):815–815. [PubMed] [Google Scholar]
  • Tarao K, So K, Moroi T, Ikeuchi T, Suyama T. Detection of endotoxin in plasma and ascitic fluid of patients with cirrhosis: its clinical significance. Gastroenterology. 1977 Sep;73(3):539–542. [PubMed] [Google Scholar]
  • Stein SF, Fulenwider JT, Ansley JD, Evatt BL, Nordlinger B, McLemore P, Schwotzer L, Wideman CS. Accelerated fibrinogen and platelet destruction after peritoneovenous shunting. Arch Intern Med. 1981 Aug;141(9):1149–1151. [PubMed] [Google Scholar]
  • Ragni MV, Lewis JH, Spero JA. Ascites-induced LeVeen shunt coagulopathy. Ann Surg. 1983 Jul;198(1):91–95.[PMC free article] [PubMed] [Google Scholar]
  • Henderson JM, Stein SF, Kutner M, Wiles MB, Ansley JD, Rudman D. Analysis of Twenty-three plasma proteins in ascites. The depletion of fibrinogen and plasminogen. Ann Surg. 1980 Dec;192(6):738–742.[PMC free article] [PubMed] [Google Scholar]
  • Puig JG, Antón FM, Fernández FA, Aguado AG, Rodriguez JJ. Peritoneovenous shunting for ascites. N Engl J Med. 1980 Aug 21;303(8):461–461. [PubMed] [Google Scholar]
  • Elin RJ, Robinson RA, Levine AS, Wolff SM. Lack of clinical usefulness of the limulus test in the diagnosis of endotoxemia. N Engl J Med. 1975 Sep 11;293(11):521–524. [PubMed] [Google Scholar]
  • Fumarola D. Coagulopathy following peritoneovenous shunting--an endotoxin medication? Surgery. 1980 Apr;87(4):475–475. [PubMed] [Google Scholar]
  • Kostroff KM, Ross DW, Davis JM. Peritoneovenous shunting for cirrhotic versus malignant ascites. Surg Gynecol Obstet. 1985 Sep;161(3):204–208. [PubMed] [Google Scholar]
  • Lacy JH, Wieman TJ, Shively EH. Management of malignant ascites. Surg Gynecol Obstet. 1984 Oct;159(4):397–412. [PubMed] [Google Scholar]
  • Schwartz ML, Swaim WR, Vogel SB. Coagulopathy following peritoneovenous shunting. Surgery. 1979 Jun;85(6):671–676. [PubMed] [Google Scholar]
  • Broadie TA, Glover JL, Bang N, Bendick PJ, Lowe DK, Yaw PB, Kafoure D. Clotting competence of intracavitary blood in trauma victims. Ann Emerg Med. 1981 Mar;10(3):127–130. [PubMed] [Google Scholar]
  • ASTRUP T, MULLERTZ S. The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys. 1952 Oct;40(2):346–351. [PubMed] [Google Scholar]
  • Moore KL, Bang NU, Broadie TA, Mattler LE, Marks CA. Peritoneal fibrinolysis: evidence for the efficiency of the tissue-type plasminogen activator. J Lab Clin Med. 1983 Jun;101(6):921–929. [PubMed] [Google Scholar]
  • Stein SF, Fulenwider JT, Ansley JD, Evatt BL, Nordlinger B, McLemore P, Schwotzer L, Wideman CS. Accelerated fibrinogen and platelet destruction after peritoneovenous shunting. Arch Intern Med. 1981 Aug;141(9):1149–1151. [PubMed] [Google Scholar]
  • Salem HH, Dudley FJ, Merrett A, Perkin J, Firkin BG. Coagulopathy of peritoneovenous shunts: studies on the pathogenic role of ascitic fluid collagen and value of antiplatelet therapy. Gut. 1983 May;24(5):412–417.[PMC free article] [PubMed] [Google Scholar]
  • Phillips LL, Rodgers JB. Procoagulant activity of ascitic fluid in hepatic cirrhosis: in vivo and in vitro. Surgery. 1979 Nov;86(5):714–721. [PubMed] [Google Scholar]
  • Ratnoff OD. Epsilon aminocaproic acid--a dangerous weapon. N Engl J Med. 1969 May 15;280(20):1124–1125. [PubMed] [Google Scholar]
  • Merlo G, Fausone G, Barbero C, Castagna B. Fibrinolytic activity of the human peritoneum. Eur Surg Res. 1980;12(6):433–438. [PubMed] [Google Scholar]
  • Laug WE. Ethyl alcohol enhances plasminogen activator secretion by endothelial cells. JAMA. 1983 Aug 12;250(6):772–776. [PubMed] [Google Scholar]
  • Matsuo O, Rijken DC, Collen D. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Thromb Haemost. 1981 Jun 30;45(3):225–229. [PubMed] [Google Scholar]
  • Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature. 1981 Jun 18;291(5816):590–591. [PubMed] [Google Scholar]
  • Weimar W, Stibbe J, van Seyen AJ, Billiau A, De Somer P, Collen D. Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator. Lancet. 1981 Nov 7;2(8254):1018–1020. [PubMed] [Google Scholar]
  • Patrassi GM, Martinelli S, Sturniolo GC, Cappellato MG, Vicariotto M, Girolami A. Fibrinolytic study in plasma and ascitic fluid of cirrhotic patients before and after ascites concentration; reinfusion technique. Eur J Clin Invest. 1985 Aug;15(4):161–165. [PubMed] [Google Scholar]
  • LeVeen HH, Vujic I, d'Ovidio NG, Hutto RB. Peritoneovenous shunt occlusion. Etiology, diagnosis, therapy. Ann Surg. 1984 Aug;200(2):212–223.[PMC free article] [PubMed] [Google Scholar]
  • Buckman RF, Woods M, Sargent L, Gervin AS. A unifying pathogenetic mechanism in the etiology of intraperitoneal adhesions;. J Surg Res. 1976 Jan;20(1):1–5. [PubMed] [Google Scholar]
  • Hau T, Payne WD, Simmons RL. Fibrinolytic activity of the peritoneum during experimental peritonitis. Surg Gynecol Obstet. 1979 Mar;148(3):415–418. [PubMed] [Google Scholar]
  • Gervin AS, Puckett CL, Silver D. Serosal hypofibrinolysis. A cause of postoperative adhesions. Am J Surg. 1973 Jan;125(1):80–88. [PubMed] [Google Scholar]
  • LeVeen HH, Ip M, Ahmed N, Mascardo T, Guinto RB, Falk G, D'Ovidio N. Lowering blood viscosity to overcome vascular resistance. Surg Gynecol Obstet. 1980 Feb;150(2):139–149. [PubMed] [Google Scholar]
  • Rajagopalan PR, Reines HD, Pulliam C, Fitts CT, LeVeen HH. Reversal of acute renal failure using hemodilution with hydroxyethyl starch. J Trauma. 1983 Sep;23(9):795–800. [PubMed] [Google Scholar]
Copyright notice
Abstract
In 1942, 53% of medically treated patients with cirrhosis were dead 6 months after the onset of ascites. Only 30% survived 1 year. This dismal outlook has improved only slightly with advances in medicine. Yet, some internists reject the peritoneovenous shunt (PVS) for this fatal condition even if they are aware that a diminished blood volume causes the abnormal sodium retention responsible for ascites. Their objections are based on life-threatening complications of PVS, especially post shunt coagulopathy (PSC). Blood shed into the peritoneal cavity becomes incoagulable. Such blood is immediately coagulated by a protocoagulant (soluble collagen) and concurrently lysed by tissue plasminogen activator (TPA) secreted by the peritoneal serosa. Wide zones of lysis surround peritoneal tissue placed on fibrin plates. Large volumes of ascitic fluid infused into circulating blood simulates the fate of blood shed into the peritoneal cavity with lysis playing the major role. Addition of ascitic fluid to normal platelet-rich plasma in vitro initiates clot lysis on thromboelastogram (TEG). Epsilon-aminocaproic acid (EACA) counteracts this lysis. EACA and clotting factors normalize the TEG and arrest PSC. Disposal of ascitic fluid at surgery prevents or ameliorates PSC. Mild PSC was encountered only twice in 150+ consecutive patients (1.3%) with only one case being clinically significant (0.6%). Severe PSC occurred seven times in 98 early shunt patients whose ascitic fluid was not discarded. Severe PSC requires shunt interruption and control of bleeding with clotting factors and EACA. Peritoneal lavage with saline prevents the recurrence of PSC on reopening the shunt. In four patients, EACA and clotting factors were adequate to arrest coagulopathy. Three earlier patients died of PSC before its cause and treatment were understood. Proper management eliminates this life-threatening complication, and PSC cannot be considered a deterrent to PVS. Disseminated intravascular coagulopathy (DIC) is produced in experimental animals only by the injection of thrombin or thromboplastin. PSC is a distinct entity differing from DIC; EACA and not heparin is the antidote for PSC.
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.